S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The 3-Stock Retirement Blueprint (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The 3-Stock Retirement Blueprint (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The 3-Stock Retirement Blueprint (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The 3-Stock Retirement Blueprint (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The 3-Stock Retirement Blueprint (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The 3-Stock Retirement Blueprint (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The 3-Stock Retirement Blueprint (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The 3-Stock Retirement Blueprint (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NYSE:ZBH

Zimmer Biomet - ZBH Price Target & Analyst Ratings

$123.35
+3.25 (+2.71%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$120.72
$123.78
50-Day Range
$104.55
$120.10
52-Week Range
$100.39
$135.05
Volume
1.42 million shs
Average Volume
1.40 million shs
Market Capitalization
$25.89 billion
P/E Ratio
93.45
Dividend Yield
0.80%
Price Target
$124.05

Zimmer Biomet Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 21 Analyst Ratings

Consensus Analyst Price Target

$124.05
0.57% Upside
High Prediction$155.00
Average Prediction$124.05
Low Prediction$95.00
TypeCurrent
12/2/21 to 12/2/22
1 Month Ago
11/2/21 to 11/2/22
3 Months Ago
9/3/21 to 9/3/22
1 Year Ago
12/2/20 to 12/2/21
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
7 Buy rating(s)
14 Buy rating(s)
Hold
14 Hold rating(s)
14 Hold rating(s)
15 Hold rating(s)
3 Hold rating(s)
Sell
3 Sell rating(s)
4 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$124.05$125.40$133.50$180.89
Predicted Upside0.57% Upside8.01% Upside11.34% Upside19.49% Upside
Get Zimmer Biomet Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.


ZBH Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZBH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zimmer Biomet Stock vs. The Competition

TypeZimmer BiometMedical CompaniesS&P 500
Consensus Rating Score
2.05
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside0.57% Upside575.39% Upside11.38% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
866
70.58%
Underperform Votes
361
29.42%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/23/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$116.00 ➝ $124.00+7.52%
11/3/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Perform$128.00 ➝ $125.00+18.04%
11/3/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$119.00 ➝ $116.00+7.72%
10/17/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderweight$104.00-5.89%
10/12/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderperform$95.00-12.30%
8/3/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$115.00 ➝ $120.00+4.94%
8/2/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$130.00 ➝ $120.00+5.24%
7/22/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$115.00+7.48%
7/18/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$140.00 ➝ $120.00+15.93%
5/27/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
3/21/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$179.00 ➝ $155.00+28.34%
3/2/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$130.00+4.72%
3/1/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderperform ➝ Underperform$120.00-3.33%
2/8/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$150.00 ➝ $114.00-0.18%
2/8/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold$140.00 ➝ $121.00+8.35%
2/8/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$175.00 ➝ $145.00+29.85%
2/8/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$165.00 ➝ $125.00+11.94%
2/8/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform$150.00 ➝ $135.00+20.89%
2/2/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$172.00 ➝ $130.00+4.85%
1/10/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
1/10/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
11/23/2021Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
9/14/2021Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
9/14/2021Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
8/4/2021Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Steven Lichtman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform$195.00 ➝ $190.00+23.61%
4/15/2021Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$165.00 ➝ $200.00+18.83%
1/4/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform$175.00+13.57%
11/9/2020Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matt Miksic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetUnderperform$99.00 ➝ $106.00-23.48%
10/27/2020Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetPositive ➝ Market Perform$130.00 ➝ $150.00+7.52%
9/11/2020Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$174.00+25.48%
5/12/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$125.00 ➝ $132.00+10.68%
4/28/2020Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
1/7/2020Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$140.00 ➝ $170.00+14.90%
(Data available from 12/2/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ZBH Price Target - Frequently Asked Questions

What is Zimmer Biomet's consensus rating and price target?

According to the issued ratings of 21 analysts in the last year, the consensus rating for Zimmer Biomet stock is Hold based on the current 3 sell ratings, 14 hold ratings and 4 buy ratings for ZBH. The average twelve-month price prediction for Zimmer Biomet is $124.05 with a high price target of $155.00 and a low price target of $95.00. Learn more on ZBH's analyst rating history.

Do Wall Street analysts like Zimmer Biomet more than its competitors?

Analysts like Zimmer Biomet less than other Medical companies. The consensus rating for Zimmer Biomet is Hold while the average consensus rating for medical companies is Buy. Learn more on how ZBH compares to other companies.

Do MarketBeat users like Zimmer Biomet more than its competitors?

MarketBeat users like Zimmer Biomet more than other Medical companies. 70.58% of MarketBeat users gave Zimmer Biomet an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Is Zimmer Biomet being upgraded by Wall Street analysts?

Over the previous 90 days, Zimmer Biomet's stock had 1 upgrade by analysts.

Does Zimmer Biomet's stock price have much upside?

According to analysts, Zimmer Biomet's stock has a predicted upside of 8.30% based on their 12-month price targets.

What analysts cover Zimmer Biomet?

Zimmer Biomet has been rated by Barclays, Citigroup, Jefferies Financial Group, Royal Bank of Canada, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:ZBH) was last updated on 12/2/2022 by MarketBeat.com Staff